ArticleMolecules (Basel, Switzerland)2025
Assessment of ADC Higher Order Structure Through 2D NMR Analysis.
Article in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- An Integrated NMR Approach for Evaluating Linker-Payload Conjugation with Monoclonal Antibodies.Bioconjugate chemistry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibody-drug conjugates (ADCs) represent a growing class of important chemotherapeutic molecules. Our understanding of the physical properties of the antibody, linker, and payload is still quite limited, but a better understanding may lead to superior ADCs. Biomolecular NMR has shown promise in the characterization of antibody higher-order structure, suggesting that the same should be true for ADCs. We applied 2D NMR techniques to trastuzumab alone and to trastuzumab conjugated to MMAE and DXd linker-payloads at drug-antibody ratios (DAR) 2, 4, and 8 to assess the effects of drug conjugation on antibody higher-order structure. Trastuzumab alone generated high-quality NMR spectra under a variety of temperatures and concentrations. Spectra of low DAR species were remarkably similar both to each other and to the free antibody, except for notable new peaks in the spectra from the linker-payloads. Increasing DAR resulted in the disappearance of many well-dispersed peaks; at the highest DAR, both T-MMAE and T-DXd showed a global broadening of signals, although this effect was more extreme in T-MMAE. These spectra demonstrate the promise of biomolecular NMR to provide a direct window into the solution behavior of ADCs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.